CHOLINERGIC PROPERTIES OF DESIPRAMINE AND AMOXAPINE: ASSESSMENT USING A THERMOREGULATION PARADIGM

STEVEN C. DILSAVER, ROBIN DAVIDSON
Mental Health Research Institute, Department of Psychiatry, University of Michigan, Ann Arbor, Michigan, U.S.A.

(Final form, April 1987)

Abstract


1. The withdrawal of tricyclic antidepressants (TCAs) produces symptoms suggesting cholinergic rebound.
2. Amitriptyline (AMI), the most potent antimuscarinic agent among this class of drugs, produces supersensitivity to the muscarinic agonist, oxotremorine.
3. Enhancement of the sensitivity of cholinceptive neurons to acetylcholine as a consequence of treatment with TCAs would account for many of the symptoms following the withdrawal of these drugs.
4. Desipramine (DMI) is the least potent antimuscarinic compound among the TCAs, yet its withdrawal produces withdrawal symptoms.
5. Recently, it was reported that amoxapine (AMX) weakly binds to muscarinic acetylcholine receptors (mAchR) in vitro. This may indicate that this drug lacks the effects antimuscarinic effects in vivo, and that it will not supersensitize cholinergic networks.
6. A thermoregulation paradigm was used to assess the sensitivity of a central muscarinic mechanism to oxotremorine before and after treatment with DMI and AMX. Treatment with either drug increased the hypothermic response to this agonist.
7. Mechanisms whereby drugs can produce cholinergic system supersensitivity, and the use of thermoregulation paradigms in assessing the properties of therapeutic agents is discussed.

Keywords: Amitriptyline, amoxapine, cholinergic, desipramine, thermoregulation paradigm

Abbreviations: amitriptyline (AMI); amoxapine (AMOX); desipramine (DMI); muscarinic acetylcholine receptor (mAchR); quinuclidnyl benzilate (QNB); tricyclic antidepressants (TCAs)

Introduction

All tricyclic antidepressants (TCAs) antagonize muscarinic cholinergic systems. The evidence for this includes the capacity of TCAs to block biochemical and physiological effects of acetylcholine (Atkinson and Landinsky, 1972; Blackwell et al., 1978; Richelson and Dininets-Romero, 1977; Szabadi et al., 1980), the specific high affinity binding of these agents to the muscarinic acetylcholine receptor (mAchR) (Snyder and Yamamura, 1977) and their propensity to produce antimuscarinic side-effects. Drugs
with these properties produce mAChR up-regulation (Ben-Barak and Dudai, 1980; Ehlert et al., 1983; Wise et al., 1980; Yamada et al., 1983) and supersensitivity of cholinceptive neurons to acetylcholine or cholinomimetic agents (Dilsaver, 1986a,b; Friedman et al., 1969; Jaffe and Sharpless, 1968) Observations that the withdrawal of TCAs can result in symptoms which are also produced by muscarinic agonists and anticholinesterases (Dilsaver and Greden, 1984a,b; Dilsaver et al., 1983a,b; Dilsaver et al., in press) is consistent with this.

Temperature is subject to regulation by a hypothalamic muscarinic mechanism (Lomax et al., 1969) which is subject to supersensitization by chronic treatment with antimuscarinic agents and subsensitization by the protracted administration of an anticholinesterase (Overstreet et al., 1973). This suggests TCAs may produce supersensitivity to muscarinic agonists and presents a strategy for assessing the capacities of psychotropics to modify the sensitivity of a central cholinergic mechanism(s) (Dilsaver, 1986a). We demonstrated this by treating rats with amitriptyline (AMI) 10 mg/kg intraperitoneally (ip) twice daily. This regime resulted in marked enhancement of sensitivity to the hypothermic effects of oxotremorine (Dilsaver et al., in press a). Treatment with AMI, 10 mg/kg ip twice daily for 26 days and 20 mg/kg ip twice daily for an additional 5 days produced a 20-fold increase in the sensitivity to oxotremorine. Supersensitization was also demonstrated by varying the dose of AMI and holding the dose of oxotremorine constant at 1 mg/kg ip (Dilsaver and Snider, 1986). The higher the dose of AMI administered the greater the hypothermic response.

The study reported in this article was designed to assess the capacities of the least potent antimuscarinic agent among the TCAs, desipramine (DMI), and the dibenzoxazepine derivative, amoxapine (AMX), to produce supersensitivity of a central muscarinic mechanism. AMX weakly displaces the mAChR antagonist, quinuclidinyl benzilate (QNB) (Coupet et al., 1985) in vitro. This implies that it may only minimally antagonize muscarinic cholinergic systems. However, drugs can produce supersensitivity of cholinergic systems without directly blocking the mAChR. Agents activating systems which inhibit the release of acetylcholine through actions on the presynaptic cholinergic neuron are among these (Dilsaver, in press). For instance, activation of dopaminergic neurons (Ehlert et al., 1981a) and treatment with isoproterenol (Nomura et al., 1982a) can increase the density of mAChRs in the striatum and myocardium of rats, respectively. AMX inhibits the uptake of norepinephrine and its withdrawal is associated with atropine-responsive symptoms suggesting cholinergic rebound (Dilsaver et al., 1983a). Thus, its effects on muscarinic mechanisms in vivo are of interest.
Temperature Measurement

Model VM Mini-Mitters (Mini-Mitter Co. Sun River OR) were implanted into the peritoneal cavity of adult male Sprague-Dawley rats. These devices emit Hertzian waves at a rate directly proportional to temperature. A transistor radio set to an AM frequency served as a receiver. Time to emit 10 sounds was measured using a digital display stopwatch. This measurement was then converted to temperature using a linear regression equation which was derived by measuring the emission rate of the thermosensors at three temperatures in a temperature controlled waterbath. These instruments can be sensitive to a change in temperature of 0.1°C (Tocco-Bradley et al., 1985).

Oxotremorine Challenge

All oxotremorine challenges were conducted between 1000 and 1100 hours and were preceded by the administration of methylscopolamine nitrate, 1 mg/kg ip to block the peripheral effects of the muscarinic agonist. Baseline temperature (i.e., time to emit 10 discrete sounds) was measured 30 minutes later. Oxotremorine (base), 1 mg/kg ip was then administered and temperature recorded every 10 minutes for 120 minutes.

Table 1 outlines steps in the preparation of Mini-Mitters, the recording of raw data, the conversion of these data to absolute core temperature and change in temperature relative to the pretreatment thermic response to oxotremorine.

Pharmaceuticals

DMI was purchased from Sigma Chemical Company (St. Louis, MO) and administered in the form of the hydrochloride. The regime of 10 mg/kg twice daily was based upon reports by Nomura et al. (1982b,1983) that it produces up-regulation of the mAChR and supersensitivity to acetylcholine in rat myocardium. AMX hydrochloride was provided as a gift by Lederle. The dose of AMX (molecular weight = 313.8) we selected presented the advantage of being essentially equimolar to the dose of DMI (molecular weight = 302.8) we used. Doses of DMI and AMX both refer to the salt form.

Animals

This study involved two samples of Sprague-Dawley rats, one of which received treatment with AMX (mean weight ± SEM = 307 ± 22.2 grams) and the other DMI (mean weight ± SEM = 316 ± 30.2 grams).

Experimental Design

The experimental design is illustrated in Figure 1. The experiment involved three phases. Phase I began with the implantation of the thermosensors and concluded after the animals had five days to recover from surgery. The first oxotremorine challenge marked the end of Phase I and beginning of Phase II. This challenge provided a baseline against which all subsequent data obtained in oxotremorine challenges was to be evaluated. During Phase II all animals were treated with either AMX or DMI.
Step 1: The Model VM Mini-Mitter is calibrated, by allowing it to come into equilibrium in a temperature controlled water bath, and measuring the rate at which it emits sounds detectable with an AM receiver at three (3) temperatures.

Step 2: The device is implanted into the peritoneal cavity and the animals are allowed 5 or more days to recover.

Step 3: The baseline (preantidepressant treatment) hypothermic response to oxotremorine (base) 1 mg/kg, intraperitoneally is measured. The data sheet is organized as follows:

<table>
<thead>
<tr>
<th>Animal</th>
<th>Mass scopolamine</th>
<th>30 min. Post injection</th>
<th>Time in seconds to emit 10 sounds</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>290 g</td>
<td>4.00</td>
<td>10 20 30 40 50 60 70 80 90 100 110 120</td>
</tr>
<tr>
<td>2</td>
<td></td>
<td>3.9</td>
<td>3.81 3.80 3.30 3.42 3.30 3.45 3.42 3.6</td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td>3.7 3.75</td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Step 4: These time measurements are used to calculate core temperature and change in core temperature relative to the baseline for a particular day. The baseline for a given day is defined by the core temperature 30 minutes after the injection of methylscopolamine (i.e., immediately prior to the injection of oxotremorine).

Step 5: \( \Delta \text{Time} \) (Time to emit 10 sounds in seconds at each time point) - (time to emit 10 sounds 30 minutes after the injection of methylscopolamine) is recorded.

<table>
<thead>
<tr>
<th>Animal</th>
<th>10 20 30 40 50 60 70 80 90 100 110 120</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>-0.10 -0.19 -0.20 -0.50 0.58 -0.70 -0.58 -0.55 -0.58 -0.40 -0.30 -0.25</td>
</tr>
<tr>
<td>2</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td></td>
</tr>
</tbody>
</table>

Step 6: \( \Delta \text{Time} \) is then converted to \( \Delta \text{Temperature} \) using the linear regression equation for the particular Mini-Mitter.

\[ y = 4.5x - 50.4 \]

where \( y \) = core temperature (°C) and \( x \) = time to emit 10 sounds

Table 1 continued on the next page
Step 7: The animals are subjected to an experimental manipulation thought to affect cholinergic systems (e.g., treatment with a drug).

<table>
<thead>
<tr>
<th>Animal</th>
<th>-0.46</th>
<th>-0.87</th>
<th>-0.92</th>
<th>-2.30</th>
<th>2.67</th>
<th>-3.22</th>
<th>-2.30</th>
<th>-2.53</th>
<th>-2.3</th>
<th>-1.84</th>
<th>-1.38</th>
<th>-1.15</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Fig. 1. This study is divided into three phases. Phase I is a period of preparation during which the Model VM Mini-Mitter is implanted into the peritoneal cavity and the animals allowed 5 days for recovery. Phase II begins with the first of 5 oxotremorine challenges. This provides the baseline against which all data obtained in all subsequent challenges is evaluated. Treatment with either AMX or DMI (10 mg/kg ip twice daily) is started at the conclusion of this challenge. The animals challenged with oxotremorine at 7 day intervals. All oxotremorine challenges follow the preceding dose of antidepressant by 17-18 hours. Challenge data entering into statistical analyses for the treatment phase is that obtained at the end of the third week of antidepressant administration or available from the challenge immediately preceding a loss of the animal from the study due to thermosensor failure or death. Phase III is a period of drug withdrawal.

mg/kg ip twice daily (at 0900 and 1700). At seven day intervals, 17-18 hours after the last dose of the antidepressant, oxotremorine challenges were repeated. This continued for three weeks. The data used in the analyses reported here were obtained at the time of the fourth oxotremorine challenge (i.e., at the conclusion of the three week period of antidepressant treatment) or at the point at which animals were lost to the study due to thermosensor failure (n=1) or in the case of one animal death. Phase III was a period of drug withdrawal. During this phase the animals were left undisturbed and untreated so that we could assess whether the effects of
antidepressant treatment were detectable one week after its discontinuation. Table 1 summarizes steps in the use of Mini-Mitters and in the process of data collection.

**Statistical Analysis**

The proportion of animals in which the hypothermic response was significantly enhanced following antidepressant treatment (a dichotomous variable with a binomial distribution), change in temperature with respect to time (i.e., significance of the mean difference) for each individual animal, the mean and mean maximum hypothermic response of the sample, and change in hypothermic response at each of the 12 time points for each sample relative to baseline (i.e., the pretreatment phase) were designated as dependent variables. Dichotomous data were assessed by applying the binomial theorem (Lipschutz, 1965; Siegel, 1956) to calculate the probability that in a given number of observations, "k", "n" outcomes would be observed where the probability of observing "n" by chance (α, the probability of a type I error) is known. The theorem allows the calculation of the probability of observing a given number of statistically significant outcomes in a given number of applications of a statistical test.

Mean change in the hypothermic response for each animal was calculated by subtracting the hypothermic response prior to treatment with DMI or AMX from the response after treatment at all of the 12 time points and averaging these. The significance of the mean for these paired differences for individual animals were assessed using Student's paired t-test. The maximum change in hypothermic response was assessed by pairing the maximum hypothermic response of each animal in the sample before treatment with its maximum response after treatment. The mean thermic response of the sample was assessed by pairing the mean thermic response of each of the animals before treatment with that at the end of treatment and after 7 days of abstinence by applying the paired t-test. All measures of variance in the results section refer to the standard deviation of the mean difference between matched pairs (Sd) (Goldstein, 1964).

**Results**

DMI. Table 2 summarizes data on the response of individual animals (n=8) to oxotremorine after treatment with DMI relative to their pretreatment baseline. Four (4) of 8 rats exhibited enhanced sensitivity to oxotremorine at the 0.01 level or less following treatment with DMI (p = 1.7 x 10^{-10}, binomial test) (Segel, 1956). The difference in the mean ($\bar{X} \pm S_d = 0.86 \pm 0.27$, t = 3.19, 6 df, p < 0.02) and mean maximum ($\bar{X} \pm S_d = 1.19 \pm 0.47$, t = 2.53, 7 df, p < 0.05) hypothermic responses were significant. After 7.5 days of abstinence the sample no longer exhibited supersensitivity to the hypothermic effect of oxotremorine. However, two of 6 animals continued to demonstrate supersensitivity to the thermic effects of oxotremorine at
Cholinergic properties of desipramine and amoxapine

<table>
<thead>
<tr>
<th>Animal Number</th>
<th>Days of Treatment When Last Challenged with Oxotremorine</th>
<th>Reason for Early Discontinuation from Study</th>
<th>Mean Hypothermic Responsea</th>
<th>DFb</th>
<th>tc</th>
<th>Pd</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>21</td>
<td>-</td>
<td>-1.18</td>
<td>11</td>
<td>-5.9</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>2</td>
<td>21</td>
<td>-</td>
<td>-1.50</td>
<td>11</td>
<td>-5.12</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>3</td>
<td>21</td>
<td>-</td>
<td>+0.32</td>
<td>11</td>
<td>+2.00</td>
<td>n.s.</td>
</tr>
<tr>
<td>4</td>
<td>21</td>
<td>-</td>
<td>+0.13</td>
<td>11</td>
<td>+0.46</td>
<td>n.s.</td>
</tr>
<tr>
<td>5</td>
<td>21</td>
<td>-</td>
<td>-0.54</td>
<td>11</td>
<td>-1.8</td>
<td>n.s.</td>
</tr>
<tr>
<td>6</td>
<td>21</td>
<td>-</td>
<td>-0.08</td>
<td>11</td>
<td>-1.6</td>
<td>n.s.</td>
</tr>
<tr>
<td>7</td>
<td>14</td>
<td>Mini-Mitter failure</td>
<td>-1.28</td>
<td>11</td>
<td>-3.76</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>8</td>
<td>7</td>
<td>Died 10-20 minutes after oxotremorine injection following 14 days of treatment</td>
<td>-0.98</td>
<td>11</td>
<td>-4.26</td>
<td>&lt;0.01</td>
</tr>
</tbody>
</table>

The mean was calculated by pairing the absolute value of the hypothermic response to oxotremorine at each of the 12 time points (10, 20, 30...120 minutes) after the injection of oxotremorine before and after treatment with DMI or AMX and subtracting the latter from the former, summing these differences and dividing by 12. Thus, the mean hypothermic response for a given animal \( \bar{X} \) is:

\[
\bar{X} + \text{SEM} = \frac{-0.64 \pm 0.24 -2.67}{0.05^e}
\]

Mean Hypothermic Response 7 days after the last dose of DMI relative to the pre-treatment baselinef

<table>
<thead>
<tr>
<th>Mean Hypothermic Responsea</th>
<th>DFb</th>
<th>tc</th>
<th>Pd</th>
</tr>
</thead>
<tbody>
<tr>
<td>-0.87</td>
<td>11</td>
<td>-4.35</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>-1.54</td>
<td>11</td>
<td>-6.16</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>+2.34</td>
<td>11</td>
<td>+9.75</td>
<td>&lt;0.001f</td>
</tr>
<tr>
<td>+0.39</td>
<td>11</td>
<td>+3.25</td>
<td>&lt;0.01f</td>
</tr>
<tr>
<td>+1.03</td>
<td>11</td>
<td>+6.06</td>
<td>&lt;0.001f</td>
</tr>
<tr>
<td>-0.03</td>
<td>11</td>
<td>-0.23</td>
<td>n.s.</td>
</tr>
</tbody>
</table>

\[
\bar{X} + \text{SEM} = + 0.09 \pm 0.57
\]

The probability that 4 or more of 8 animals would exhibit supersensitive responses to oxotremorine is 6.7 x 10^(-7).

(a) This mean was calculated by pairing the absolute value of the hypothermic response to oxotremorine at each of the 12 time points (10, 20, 30...120 minutes) after the injection of oxotremorine before and after treatment with DMI or AMX and subtracting the latter from the former, summing these differences and dividing by 12. Thus, the mean hypothermic response for a given animal \( \bar{X} \) is:

\[
\bar{X} + \text{SEM} = \frac{-0.64 \pm 0.24 -2.67}{0.05^e}
\]

(b) DF, Degrees of Freedom = 12 time points -1 = 11

(c) This statistic is calculated using the formula for Student's paired t-test. The measure of variance entering into the calculation is based on the standard deviation of the difference, Sd, in the hypothermic response to oxotremorine at the 12 time points before and after treatment with DMI or AMX.

(d) p values refer to the two-tailed probabilities of a type I error.
(e) The mean in this row = \(\Sigma\) \((\text{mean hypothermic response of each individual animal before treatment with DMI or AMX}) - (\text{mean hypothermic response of each individual animal after treatment with DMI or AMX})\) / 12
\(t\) was calculated using the formula for Student's paired \(t\)-test.

(f) Denotes a hyperthermic response

\(\alpha < 0.01\) and 3 of 6 exhibited significant decreases in the hypothermic response to this drug at the 0.01 level. Thus, the animals comprising the sample demonstrated marked variability in their responses to oxotremorine at this time.

Treatment with DMI was associated with a significant increase in the hypothermic response 70 (\(p < 0.001\)), 80 (\(p < 0.01\)), 90 (\(p < 0.02\)), 100 (\(p < 0.02\)), 110 (\(p < 0.02\)) and 120 (\(p < 0.001\)) minutes after the injection of oxotremorine. The probability of 6 of 12 measurements being significant at \(\alpha < 0.02\) is \(8.7 \times 10^{-10}\) (binomial test). Figure 2 illustrates the difference in the mean thermic response to oxotremorine across time after treatment with DMI relative to the pretreatment baseline. These data are presented with additional statistical information in Table 3.

AMX. Table 4 summarizes data on the responses of individual animals (\(n = 9\)) to oxotremorine after treatment with AMX relative to their pretreatment baseline. Five of 9 animals exhibited an enhanced hypothermic response at the 0.05 level or less (\(p = 1.92 \times 10^{-8}\), binomial test). The mean hypothermic response (\(X \pm S_d = 0.56 \pm 0.19^\circ C, t = 2.94, 6\) df, \(p < 0.05\)) increased significantly. There was also a trend toward a significant increase in the maximum hypothermic response (\(X + S_d = 0.61 \pm 0.31^\circ C, t = 1.96, 8\) df, \(p < 0.10\)) to oxotremorine. Following the 7.5 day withdrawal phase, the sample did not evidence enhanced responsiveness to oxotremorine.

Treatment with AMX was associated with an increase in the hypothermic response 60 (\(p < 0.02\)), 70 (\(p < 0.001\)), 80 (\(p < 0.01\)), 90 (\(p < 0.01\)), 100 (\(p < 0.01\)), 110 (\(p < 0.02\)) and 120 (\(p < 0.02\)) minutes after the injection of oxotremorine. The probability of 7 of 12 measurements being significant at \(\alpha < 0.02\) is \(8.0 \times 10^{-12}\). Figure 3 illustrates the difference between the mean thermic response to oxotremorine across time before and after treatment with AMX. These data are presented with additional statistical information in Table 5.

Discussion

Thermoregulation Paradigm

A thermoregulation paradigm and four dependent variables (1) the proportion of animals exhibiting a significant hypothermic responses at the level of \(\alpha < 0.05\), (2) the difference in the mean hypothermic response of each individual animal over time after the injection of oxotremorine before and after antidepressant treatment, (3) the mean change and mean maximum difference in the hypothermic responses of a sample before and after DMI or AMX administration, and (4) change in the hypothermic response
DIFFERENCE BETWEEN THE ABSOLUTE VALUES OF THE HYPOTHERMIC RESPONSE BEFORE AND AFTER TREATMENT WITH DMI

Fig. 2. Mean change in the thermic response $+ S_d$ at 10 minute intervals following the injection of oxotremorine, 1 mg/kg ip in animals treated with DMI (N=8).

Table 3
Change in the Mean Thermic Response ($^\circ$C) $+ S_d$ Across Time After Treatment with Desipramine

<table>
<thead>
<tr>
<th>Minutes after the injection of oxotremorine</th>
<th>10 minutes</th>
<th>20 minutes</th>
<th>30 minutes</th>
<th>40 minutes</th>
<th>50 minutes</th>
<th>60 minutes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>-0.02 $\pm$ 0.19</td>
<td>-0.02 $\pm$ 0.26</td>
<td>-0.10 $\pm$ 0.17</td>
<td>-0.14 $\pm$ 0.26</td>
<td>-0.2 $\pm$ 0.39</td>
<td>-0.68 $\pm$ 0.41</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Minutes after the injection of oxotremorine</th>
<th>70 minutes</th>
<th>80 minutes</th>
<th>90 minutes</th>
<th>100 minutes</th>
<th>110 minutes</th>
<th>120 minutes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>-1.18 $\pm$ 0.16</td>
<td>-1.43 $\pm$ 0.32</td>
<td>-1.22 $\pm$ 0.35</td>
<td>-1.57 $\pm$ 0.45</td>
<td>-1.27 $\pm$ 0.39</td>
<td>-1.41 $\pm$ 0.25</td>
</tr>
</tbody>
</table>

This table lists the change in the mean hypothermic response $+ S_d$, relative to baseline, at each of 12 time points for animals treated with DMI. Temperature was measured every 10 minutes after the injection of oxotremorine (at t = 0). Probability statements are based on the results of Student's paired t-test in which the thermic responses before and after antidepressant administration were the matched pairs, and the mean difference in the absolute value of the thermic response before and after treatment constitutes the mean effect of treatment.
### Table 4
Summary of Statistical Analysis of Data Collection on Animals Treated with Amoxapine

<table>
<thead>
<tr>
<th>Animal Number</th>
<th>Days of Treatment When Last Challenged with Oxotremorine</th>
<th>Reason for Early Discontinuation from Study</th>
<th>Mean Hypothermic Response$^a$</th>
<th>$DF_b$</th>
<th>$t_c$</th>
<th>$P_d$</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>21</td>
<td>–</td>
<td>$-0.78$</td>
<td>11</td>
<td>$-3.9$</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>2</td>
<td>21</td>
<td>–</td>
<td>$-1.46$</td>
<td>11</td>
<td>$-9.13$</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>3</td>
<td>21</td>
<td>–</td>
<td>$+0.38$</td>
<td>11</td>
<td>$+1.9$</td>
<td>n.s.</td>
</tr>
<tr>
<td>4</td>
<td>21</td>
<td>–</td>
<td>$-0.82$</td>
<td>11</td>
<td>$-4.1$</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>5</td>
<td>21</td>
<td>–</td>
<td>$-0.83$</td>
<td>11</td>
<td>$-3.95$</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>6</td>
<td>21</td>
<td>–</td>
<td>$+0.21$</td>
<td>11</td>
<td>$+1.05$</td>
<td>n.s.</td>
</tr>
<tr>
<td>7</td>
<td>21</td>
<td>–</td>
<td>$-0.37$</td>
<td>11</td>
<td>$-1.00$</td>
<td>n.s.</td>
</tr>
<tr>
<td>8</td>
<td>21</td>
<td>–</td>
<td>$-1.08$</td>
<td>11</td>
<td>$-3.96$</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>9</td>
<td>21</td>
<td>–</td>
<td>$-0.52$</td>
<td>11</td>
<td>$-2.36$</td>
<td>&lt;0.05</td>
</tr>
</tbody>
</table>

$^a$ Mean Hypothermic Response 7 days after the last dose of DMI relative to the pre-treatment baseline. 

$^b$ $X + \text{SEM} = -0.57 \pm 0.19$

$^c$ The probability of one or more of 9 animals exhibiting a decreased hypothermic response to oxotremorine at $\alpha < 0.05 = 0.044$. 

$^d$ The probability of 6 of 9 animals exhibiting significance at $\alpha < 0.05 = 1.11 \times 10^{-6}$. 

$\ast$ This animal exhibited a significant decrease in its hypothermic response after treatment.

---

This table lists the mean difference between the absolute value of the mean hypothermic response to oxotremorine before and after treatment with AMX. Please see the footnote to Table 2 for further details.
DIFFERENCE OF THE ABSOLUTE VALUES OF THE HYPOTHERMIC RESPONSE BEFORE AND AFTER TREATMENT WITH AMX

Fig. 3. Mean difference ± S_d between the hypothermic response to oxotremorine 1 mg/kg at baseline (prior to treatment) and after 21 days of treatment with AMX 10 mg/kg ip twice daily (N=9).

Table 5
Change in the Mean Thermic Response (°C) ± S_d Across Time After Treatment with Amoxapine

<table>
<thead>
<tr>
<th>Minutes after the injection of oxotremorine</th>
<th>10 minutes</th>
<th>20 minutes</th>
<th>30 minutes</th>
<th>40 minutes</th>
<th>50 minutes</th>
<th>60 minutes</th>
<th>70 minutes</th>
<th>80 minutes</th>
<th>90 minutes</th>
<th>100 minutes</th>
<th>110 minutes</th>
<th>120 minutes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>-0.14 ± 0.17</td>
<td>-0.68 ± 0.32</td>
<td>-1.40 ± 0.29</td>
<td>-0.35 ± 0.33</td>
<td>-0.02 ± 0.35</td>
<td>-0.74 ± 0.23</td>
<td>-1.16 ± 0.18</td>
<td>-1.24 ± 0.24</td>
<td>-1.38 ± 0.33</td>
<td>-0.99 ± 0.23</td>
<td>-0.96 ± 0.27</td>
<td>-0.87 ± 0.25</td>
</tr>
<tr>
<td></td>
<td>p &lt; 0.10</td>
<td>p &lt; 0.05</td>
<td>p &lt; 0.01</td>
<td>p &lt; 0.01</td>
<td>p &lt; 0.01</td>
<td>p &lt; 0.01</td>
<td>p &lt; 0.10</td>
<td>p &lt; 0.01</td>
<td>p &lt; 0.01</td>
<td>p &lt; 0.01</td>
<td>p &lt; 0.01</td>
<td>p &lt; 0.01</td>
</tr>
</tbody>
</table>

This table lists the mean change in the hypothermic response ± S_d at each of 12 time points after the injection of oxotremorine for animals treated with AMX. For additional details please see the footnote to Table 3.
at each of 12 time points (10, 20, 30...120 minutes) after the administration of oxotremorine were useful in studying the influence of a TCA and a second generation antidepressant reported to minimally interact with the mAChR on a central cholinergic mechanism. Both agents produce supersensitivity of a cholinergic mechanism involved in the regulation of core temperature. This is presumably due to central muscarinic effects of these antidepressants. First, the hypothermic response to oxotremorine is not blocked by methylscopolamine, but is by scopolamine (Dilsaver et al., in press,a). Though oxotremorine may have weak nicotinic effects (Bowman and Rand, 1980) and a TCA, amitriptyline produces supersensitivity to the hypothermic effects of nicotine (Dilsaver et al., in press, Dilsaver and Snider, 1986), activation of a nicotinic mechanism by oxotremorine is not a plausible explanation for the findings reported here. We demonstrated that pretreatment with mecamylamine, 2.5 mg/kg ip increases the hypothermic response to oxotremorine (Dilsaver and Snider, 1986; Dilsaver et al., in press b). This suggests either that oxotremorine's weak nicotinic effects partially antagonize its muscarinic effects or that its muscarinic effects result in a compensatory response by an endogenous nicotinic mechanism. For example, muscarinic stimulation inhibits the release of norepinephrine whereas nicotinic agonists promote the release of this neurotransmitter within the hypothalamus (Westfall, 1973). In conclusion, these data strongly suggest that both DMI and AMX produce supersensitivity of a central muscarinic cholinergic mechanism.

**Mechanism of Action**

Additional data suggests that DMI produces cholinergic system supersensitivity in man and animals. Chronic treatment with DMI enhances the miotic response to pilocarpine in depressed subjects (Dilsaver and Greden, 1983; Shur et al., 1983). Nomura et al. (1982b; 1983) reported that treatment with DMI, 10 mg/kg ip twice daily increases the negative ionotropic effects of acetylcholine and produces an exaggerated increase in the activity of ornithine decarboxylase in response to a cholinergic agonist. The discontinuation of DMI also produces withdrawal symptoms suggestive of cholinergic overdrive (Dilsaver et al., 1983a,b; Dilsaver and Greden, 1984a,b; Dilsaver et al., in press b). AMX produces a low incidence of "antimuscarinic-like" side effects (PDR, 1986) and its discontinuation has also been associated with withdrawal symptoms which suggest cholinergic rebound (Dilsaver et al., 1983a).

Mechanisms whereby antidepressants produce up-regulation or supersensitivity of cholinergic systems can be classified according to the site of their effect. Drugs may act postsynaptically to block the mAChR or presynaptically to inhibit the release of acetylcholine (Dilsaver, in press). Classical antimuscarinic agents such as scopolamine or atropine (Ben-Barak and Dudai, 1980; Ehlert et al., 1983; Wise et al., 1980; Yamada et al., 1983) and related compounds such as the TCAs (Goldman and Erickson, 1983; Rehavai et al., 1980; Nomura et al., 1982b, 1983) which bind with
specificity to mAchRs all denervate cholinceptive neurons by competitively antagonizing the action of acetylcholine at the postsynaptic sites. This results in a compensatory response involving an increased density of mAchR radioligand binding sites and supersensitivity (Friedman et al., 1969; Jaffe and Sharpless, 1968; Sitaram et al., 1979; Gillin et al., 1979; Innes and Nickerson, 1975) to cholinergic agonists.

The second category of agents producing up-regulation and supersensitivity of muscarinic cholinergic systems is comprised of at least five classes of agents which act at the presynaptic nerve terminal to inhibit the release of acetylcholine (Dilsaver, in press). Opiate agonists (Domino and Wilson, 1973; Jhamandas et al., 1973a,b), cannabinoids (Kumbarachi and Nastuk, 1980; Layman and Milton, 1971; Yoshimura et al., 1974), barbiturates (Nordberg and Wahlstrom, 1981; Nordberg and Sundwall, 1977; Wahlstrom and Nordberg, 1979; Wahlstrom and Ekwall, 1976; Wahlstrom, 1978), ethanol (Rabin et al., 1980; Smith, 1983; Tabakoff et al., 1979), and certain serotonergic (Ögren et al., 1985a,b), dopaminergic (Ehlert et al., 1981) and adrenergic (Blosser, 1983) agonists are in this class. Nomura et al. (1982a), for example, reported that isoproterenol induced cholinergic system supersensitivity and up-regulation of QNB binding sites in rat myocardium. Blosser (1983) found that activation of β-adrenergic receptors increased the density of cholinoreceptors in chick myotubes. These reports are consistent with the capacity of norepinephrine (Bean et al., 1978) to inhibit the release of acetylcholine from brain slices. Dopamine (Bluth and Langnicke, 1985b; Baud et al., 1985) and serotonergic (Vizi et al., 1981) agonists also reduce the release of acetylcholine in the mammalian brain. Ehlert et al. (1981b) reported that dopaminergic agonists produced an increased density of mAchR binding sites in the corpus striatum of rodents. Ögren et al. (1985a,b) reported that chronic treatment with a serotonergic agonist produced enhanced sensitivity to the tremoregic effects of muscarinic agonists. Thus, it is conceivable that DMI or AMX could produce supersensitivity to oxotremorine by either directly blocking the postsynaptic mAchR or through an effect on the presynaptic neuron. However, Coupet et al. (1985) reported that amoxapine weakly displaces QNB in mAchR binding studies. Thus, the mechanism whereby AMX produces supersensitivity to oxotremorine may indeed involve diminution in the release of acetylcholine.

These data have several theoretical implications. First, they illustrate that in vitro and in vivo studies can yield strikingly different results. The in vitro data suggest that AMX would have minimal cholinergic effects but the measure of a functional index indicates otherwise. However, seemingly contradictory in vitro and physiological data are reconcilable. AMX may act presynaptically to partially denervate postsynaptic cholinergic neurons. Secondly, Cohens and Baldessarini (1985) recently reported that tolerance sometimes develops to the antidepressant effects of TCAs. Data suggest that supersensitivity of cholinergic systems may be involved in
the pathophysiology of affective disorders (Dilsaver, 1986a-d). Enhancement of the sensitivity of cholinergic systems by antidepressants might increase the probability of depressive relapse. Third, physiological models, such as the thermoregulation paradigm set forth in this article, can be used to evaluate new antidepressants for their capacity to modify the sensitivity of cholinergic networks. Such models could have considerable value in the pre-clinical evaluation of pharmacological agents.

Conclusions

Rats were treated with DMI 10 mg/kg ip twice daily or AMX 10 mg/kg ip twice daily for up to 21 days after the baseline thermic response to oxotremorine, 1 mg/kg ip was determined. Temperature was measured telemetrically every 10 minutes for 120 minutes after the injection of oxotremorine. Oxotremorine challenges were repeated at 7 day intervals. Both groups of animals demonstrated enhanced sensitivity to the hypothermic effects of the cholinomimetic. The thermoregulation paradigm employed in this report has now demonstrated the capacity of AMI, DMI and AMX to produce supersensitization of a central cholinergic mechanism. The paradigm is applicable to the evaluation of novel antidepressants with unknown effects on muscarinic mechanisms.

Thermoregulation paradigms are applicable to the study of an array of problems. For instance, a thermoregulation paradigm was used to demonstrate that chronic treatment with AMI enhances sensitivity to the hypothermic effects of nicotine (Dilsaver and Snider, 1986; Dilsaver et al., in press b). Methods presented in this article were also used to establish that chronic forced swim stress (Dilsaver et al., 1986b) and inescapable footshock produce supersensitivity (Dilsaver and Alessi, in press b) of a central muscarinic mechanism. Thus, a thermoregulation paradigm is useful as a means of studying the pharmacology of antidepressants, the neurobiology of chronic stress or other manipulations affecting cholinergic mechanisms. It is noteworthy that the paradigm we used generated data indicating that AMX, a drug which weakly interacts with the mAchR produces supersensitivitiy of a central muscarinic mechanism. An in vitro study would suggest otherwise. The measurement of a physiological parameter sensitive to both pre- and post-synaptic actions of a manipulation can convey information that the measurement of binding variables does not.

Acknowledgements

Please direct all correspondence and request for reprints to Dr. Dilsaver at the above address. Supported in part by Physician-Scientist Career Development Award (Muscarinic Receptor Abnormalities in Affective Illness) Grant #SRCK11 MH00553-01.
References


Inquiries and reprint requests should be addressed to:

Dr. Steven C. Dilsaver
Mental Health Research Institute
Department of Psychiatry
Univ. of Michigan
205 Washtenaw Place
Ann Arbor, MI 48109-0010
U.S.A.